** U.S.-listed shares of Australia's Telix Pharmaceuticals TLX.AX, TLX.O up 30% at $25.33

** Co says the Norway's regulatory authority has granted marketing authorization to co's prostate cancer imaging agent, Illuccix

** Illuccix is already approved by the U.S. FDA in Oct. 2024

** TLX has more than doubled in the last 12 months

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatol@thomsonreuters.com))